GlassScriptPhysician profile
Luis Enrique Chug
NPI 1326207648
$9,597.10
in general payments reported to CMS, 2019-2025
30 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $374 · 2021: $1,563 · 2022: $1,107 · 2023: $888 · 2024: $3,035 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207 · Consulting Fee: $1,950 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.35 |
| Consulting Fee | $1,950.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,064.09 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,106.33 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $882.66 | 2019-2025 | Ofev |
| Electromed, INC. | $683.18 | 2019-2025 | Smartvest |
| Genzyme Corporation | $571.48 | 2019-2025 | |
| Philips North America LLC | $543.63 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy, (8874) Incourage |
| Actelion Pharmaceuticals US, INC. | $412.77 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $284.24 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $279.33 | 2021-2025 | Dupixent |
| Amgen INC. | $275.29 | 2023-2025 | Tezspire, Tavneos, Repatha |
| Shionogi INC | $230.06 | 2022-2025 | Fetroja |
| Jazz Pharmaceuticals INC. | $215.16 | 2019-2023 | |
| Harmony Biosciences LLC | $173.24 | 2022-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $162.70 | 2019-2023 | Xarelto |
| Insmed, INC. | $157.87 | 2021-2025 | Arikayce, Brinsupri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $81.45 | 2024-2025 | Lumryz |
| United Therapeutics Corporation | $69.45 | 2021 | |
| Sunovion Pharmaceuticals INC. | $55.32 | 2019-2020 | |
| Pfizer INC. | $52.79 | 2019 | |
| Grifols USA, LLC | $46.09 | 2024-2025 | Prolastin-C Liquid |
| Zoll Respicardia, INC. | $38.97 | 2023 | Remede System |
| Inspire Medical Systems, INC. | $37.13 | 2023-2024 | Inspire |
| Phadia US INC. | $36.70 | 2019-2024 | Immunocap |
| Genentech USA, INC. | $28.81 | 2019 | |
| Vapotherm INC | $25.62 | 2022 | |
| Greer Laboratories, INC. | $20.79 | 2024 | Oralair |
| Merck Sharp & Dohme LLC | $19.56 | 2023 | |
| Verona Pharma, INC. | $17.28 | 2025 | Ohtuvayre |
| Circassia INC. | $14.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Chug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.